What is the recommended intravenous iron infusion protocol for an adult with iron‑deficiency anemia (hemoglobin <11 g/dL, ferritin <30 ng/mL, transferrin saturation <20%)?

Intravenous Iron Infusion Protocol for Iron Deficiency Anemia

For an adult with iron deficiency anemia (hemoglobin <11 g/dL, ferritin <30 ng/mL, transferrin saturation <20%), administer a total dose replacement of intravenous iron using ferric derisomaltose (1000-1500 mg based on body weight, up to 20 mg/kg) or ferric carboxymaltose (1000 mg maximum per dose) as a single infusion or two doses one week apart. 1

Formulation Selection

The modern high-dose IV iron formulations allow for rapid iron repletion with minimal infusions:

• Ferric derisomaltose (FDI): Preferred option as it is the only formulation with FDA approval for total dose infusion, allows up to 1500 mg in a single dose (20 mg/kg, not to exceed 1500 mg), and has demonstrated cardiovascular mortality benefit in heart failure patients 1

• Ferric carboxymaltose (FCM): Alternative option allowing 1000 mg maximum per single dose (20 mg/kg or 1000 mg, whichever is lower), typically requiring two doses one week apart for total repletion 2, 1

Critical caveat: Avoid FCM for patients requiring repeat infusions due to treatment-emergent hypophosphatemia 1. FDI does not carry this risk.

Administration Protocol

Dosing

Calculate total iron deficit or use weight-based dosing:

• FDI: 1000-1500 mg as single infusion (up to 20 mg/kg)
• FCM: 1000 mg, repeat in 1 week if needed (total 1500-2000 mg)
• Dilute in 100 mL normal saline
• Infusion time: 15-30 minutes 1

No Test Dose Required

Modern formulations (FDI, FCM) do not require test dosing 2, 1. Older formulations like iron dextran and iron sucrose require test doses and longer infusion times, making them less practical.

Monitoring Protocol

Initial Response Assessment (4-8 weeks post-infusion)

• Do not check iron parameters within 4 weeks of infusion—circulating iron interferes with assays leading to spurious results 1
• Check complete blood count at 4-8 weeks
• Expected hemoglobin increase: 1-2 g/dL within 4-8 weeks 1
• Check ferritin and transferrin saturation at 4-8 weeks

Target values without inflammation:

• Ferritin ≥50 ng/mL
• Transferrin saturation ≥20% 1

Long-term Monitoring

After hemoglobin normalizes 2:

• Every 3 months for 12 months
• Then every 6 months for 2-3 years
• This detects recurrent deficiency indicating ongoing blood loss or malabsorption

Clinical Context Modifications

Severe Anemia (Hemoglobin <7 g/dL)

High-dose IV iron (1500 mg ferric carboxymaltose) is effective and safe even in severe anemia, avoiding transfusion in hemodynamically stable patients 3. Mean hemoglobin increase of 5.7 g/dL achieved with 1500 mg iron 3.

Ongoing Blood Loss or Malabsorption

If the underlying cause persists (heavy menstrual bleeding, inflammatory bowel disease, post-bariatric surgery):

• Repeat infusions will be necessary
• Frequency depends on degree of loss
• Monitor every 3 months initially 2

Inflammatory Conditions

In inflammatory bowel disease or chronic disease 2:

• Ferritin up to 100 ng/mL may still reflect iron deficiency
• Use transferrin saturation <20% as primary diagnostic criterion
• IV iron preferred over oral due to impaired absorption

Heart Failure

Screen all heart failure patients for iron deficiency (ferritin <100 μg/L and/or transferrin saturation <20%) 2:

• Use IV iron exclusively—oral iron shows no prognostic benefit and is poorly absorbed
• IV iron improves functional capacity, quality of life, and reduces cardiovascular events 2, 1

Safety Considerations

Hypersensitivity reactions are rare (<1%) with modern formulations 1, 4. Observe patients during and for 30 minutes after infusion for:

• Minor infusion reactions (flushing, nausea, myalgias)
• Serious allergic reactions (extremely rare: 0.04% in real-world data) 5

No premedication required for FDI or FCM 1.

Common Pitfalls

1. Underdosing: Real-world data shows patients often receive less iron than needed—mean dose 1244 mg when estimated need was 1580 mg, resulting in persistent anemia in >65% of cases 5. Calculate and administer full iron deficit.

2. Premature laboratory testing: Checking iron parameters within 4 weeks yields unreliable results 1.

3. Using oral iron first in inappropriate patients: IV iron is first-line for inflammatory bowel disease with moderate-severe anemia (Hb <100 g/L), heart failure, intolerance to oral iron, and malabsorption 2.

4. Switching between oral iron salts: No evidence supports this practice for oral intolerance—switch to IV iron instead 2.